Selux Diagnostics announced it raised $40 Million in an initial filing from an offering of $45 Million

Company

Location

About

The Selux platform will become the system of choice for healthcare providers dedicated to providing best-in-class septic and other infectious diseases patient care." In September 2021, the company received Breakthrough Device Designation from the FDA for positive blood culture and sterile body fluid sample indications for NGP. In October 2021, the company received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help commercialization efforts.